Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia.
Chestnykh D, Mühle C, Schumacher F, Kalinichenko LS, Löber S, Gmeiner P, Alzheimer C, von Hörsten S, Kleuser B, Uebe S, Ekici AB, Gulbins E, Kornhuber J, Jin HK, Bae JS, Lourdusamy A, Müller CP.
Chestnykh D, et al. Among authors: jin hk.
Mol Psychiatry. 2025 Jan 17. doi: 10.1038/s41380-025-02893-6. Online ahead of print.
Mol Psychiatry. 2025.
PMID: 39825014